Genes Associated with m6A Modifications Indicate Prognostic Risk and Immune Modulation in Lung Adenocarcinoma

• by Xiaoxing Liu, Shanshan Li, Min Zhou, Ning Ding, Jinzhong Chen, Ning Zhou

• January 16, 2026

Signals of inequity in the care pathway: rural lab diagnosis, systemic therapy delays, and RAS mutation differences in metastatic colorectal cancer

• by Adam Ismail, Amandri Dahanayake, Shahid Ahmed, Yagan Pillay, Areej Khatib

• June 2, 2026

Lymph Node Dissection and Postoperative Complications After Lung Cancer Resection

• by Isheeta Madeka, Khaled Noueihed, Jacob Woodroof, Shale Mack, Hamza Rshaidat, Gregory L. Whitehorn, Sneha Alaparthi, Scott H. Koeneman, Tyler R. Grenda, Nathaniel R. Evans, Olugbenga T. Okusanya

• June 1, 2026

Perioperative Apalutamide in High-Risk Localized or Locally Advanced Prostate Cancer Reduces Risk of Metastasis and Death

High-risk localized and locally advanced prostate cancer patients treated with apalutamide — a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) — plus hormone therapy before and after prostate cancer surgery resulted in more major pathologic responses and reduced the risk of metastasis or death, meeting both primary endpoints, in an international phase 3 clinical trial led by principal investigator Mary-Ellen Taplin, MD, medical oncologist at Dana-Farber Cancer Institute, and Adam Kibel, MD, chair of the Department of Urology at Mass General Brigham.

• by

• June 1, 2026

• 4 min